Beth Hite, NP
Payments from drug & device makers
Across 367 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Dexcom, Inc.$1K
- Lilly USA, LLC$745
- Amgen$702
- Medtronic$568
- Abbott$558
- plus $3K from 26 others
What the payments were for
- Food & beverage$8,651100%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 88 | $1,613 |
| Dexcom, Inc. | 38 | $1,308 |
| Lilly USA, LLC | 53 | $745 |
| Amgen(2 entities) | 35 | $702 |
| Medtronic | 12 | $568 |
| Abbott | 29 | $558 |
| Tandem Diabetes Care, Inc. | 9 | $419 |
| Insulet Corporation | 11 | $403 |
| Inspire Medical Systems, Inc. | 3 | $342 |
| Mannkind Corporation | 18 | $265 |
| AstraZeneca | 8 | $257 |
| BETA Bionics, Inc. | 5 | $182 |
| Boehringer Ingelheim | 4 | $160 |
| Xeris Pharmaceuticals, Inc. | 10 | $155 |
| Sanofi-aventis U.S. LLC | 6 | $132 |
| Bayer | 7 | $129 |
| Boston Scientific | 1 | $123 |
| Astellas Pharma US Inc | 2 | $117 |
| Novartis | 5 | $99 |
| Recordati_rare_diseases_inc. | 4 | $70 |
| Amarin Pharma, Inc. | 4 | $68 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| IBSA Pharma Inc. | 2 | $38 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Merck | 2 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Halozyme Inc | 1 | $20 |
| Antares Pharma, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $18 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$823
- iLet Bionic Pancreas$356
- Inspire$295
- INTELLIS ADAPTIVESTIM$159
- Omnipod$150
- FREESTYLE LIBRE 3$141
- LUX-Dx Insertable Cardiac Monitor$123
- EVENITY$122
- AFREZZA$118
- DEXCOM G7 GSS (161)$115
- DEXCOM STELO GLUCOSE BIOSENSOR$115
- t:slim X2 Insulin Pump with Control-IQ$112
- FARXIGA$106
- Saxenda$106
- RYBELSUS$102
How this compares
$8,688 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 378 | $607,581 |
| MounjaroTirzepatide | 264 | $358,388 |
| JardianceEmpagliflozin | 322 | $341,373 |
| FarxigaDapagliflozin Propanediol | 294 | $257,905 |
| TrulicityDulaglutide | 187 | $257,106 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 213 | $240,878 |
| Tresiba Flextouch U-200Insulin Degludec | 117 | $228,382 |
| RybelsusSemaglutide | 105 | $186,757 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 104 | $181,010 |
| JanuviaSitagliptin Phosphate | 120 | $93,168 |
| Tresiba Flextouch U-100Insulin Degludec | 130 | $81,598 |
| Humalog Kwikpen U-200Insulin Lispro | 37 | $70,322 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 43 | $69,556 |
| Bydureon BciseExenatide Microspheres | 29 | $44,276 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $43,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $1,613 | $827,275571 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro | $745 | $655,714607 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $160 | $445,334421 claims |
| AstraZenecaFarxiga | $257 | $257,905294 claims |
| MerckJanuvia, Janumet Xr | $28 | $108,111140 claims |
| Antares Pharma, Inc.Tlando | $18 | $8,77912 claims |
| Amneal Pharmaceuticals LLCUnithroid | $37 | $5,501120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Salem
- Neeta VorstSalem$18K
- Kelly LinkSalem$11K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.